With the state of cryptocurrencies at the moment and the market recovery on the verge of getting a foothold, it’s time, atleast in my opinion to start taking a look at some of the promising projects that will be running their ICO over the summer months. If we see a full recovery in the market and a nice run leading into the end of the year, these projects will be perfectly placed to see some great profit margins.
I will be running another series alongside this one, with in depth reviews of each project starting at some point before the start of May.
Check out Badman ICOs #1 - XYO Network Overview
Check out Badman ICOs #2 - Acorn Collective Overview
For the third in the series on ICOs, I’d like to cover a project that has been gaining a huge amount of attention over the last couple of weeks and has just raised a massive $33.1 Million in their public pre-sale - Project Shivom.
Genomic medicine is a rapidly growing area of medicine that can be used to enhance the understanding and treatment of a multitude of rare diseases, cancers, cardiovascular and neurodegenerative conditions, and infections and change the future of the health industry forever. Similarly, blockchain technology has the potential to transform many aspects of society and the world economy: it looks set to accomplish the biggest transformation in innovation since the advent of the internet.
Shivom brings these emerging technologies together to build a revolutionary medical genomics ecosystem that aims to open up healthcare opportunities to everyone. The platform will facilitate a person’s genome sequencing, with the data being written onto the blockchain and owned by the donor. This allows donors to gain rewards by sharing their data with third party institutions such as pharmaceutical companies.
The Shivom platform uses of a utility token (OMX) with the official token sale running between May 03rd and May 10th 2018. The pre-sale was live between 16th and 27th of April and sold a massive $33.1 million worth (94% of ICO hard cap).
The ICO is be priced using a flat pricing structure of 7,000 OMX equalling 1 ETH. The token makes use of an ERC20 smart contract based on the Ethereum blockchain with a ICO hard cap of 990 million OMX tokens and total supply of 3 billion OMX.
The process looks extremely easy and will involve signing up for the program and receiving a kit in the mail to collect a saliva sample. After sending it for testing, the donor can donate their genome to research for free or for profit. Other services will include an ancestry report and personal health insights.
Data will be secured on the blockchain and owned by the donor who will also have full control over access rights and can be shared on the blockchain by selling access rights to a third party. Pharmaceutical companies can then use the Shivom platform to refine drug development. This will lead to a dynamic ecosystem where the community can identify and remove potential health roadblocks at an early stage.
The project has a strong team that have a lot of experience in their respective fields with DR. Axel Schumacher CEO. Dr. Schumacher has an impressive resume with a Ph.D in Genetics and over 20 years of R&D experience in varying areas of biomedical science. There is currently no MVP although the roadmap states that it is scheduled to be released in Q2 of 2018.
For more info about the project, check out the links below to visit the website and check out the whitepaper and if you have any questions you can ask the team directly on their telegram channel. Alternatively check out the ANN and Bounty threads on Bitcointalk forums.
Badman Crypto (Phil Stephenson):
Twitter
Facebook
Bitcointalk profile
Telegram
ETH: 0xea5924b2a0b977604c9dd02fd4723cf92767a083
NEO: AWoF9Jaj4UchBG9iTkL54NjM6UgoX9yTpW